RxDoctor Payments Data

Joseph Dimenna, DPM

Podiatrist · Cherry Hill, NJNPI 1205873155

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,761 of the $5,424 with a category attached, or 87.8%. 43 manufacturers reported payments, led by Stryker at 30.8% of the total. Reporting peaked in 2024 at $1,673 and has fallen 63.3% since, to $615 in 2025.

$5,424in general payments, 2019–2025

Across 216 payments — averaging $25.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Organogenesis Inc.$742
  • Smith+Nephew$442
  • Paratek Pharmaceuticals, Inc.$415
  • Zimmer Biomet$262
  • Amgen$179
  • plus $2K from 37 others

What the payments were for

  • Travel & lodging$66312%
  • Food & beverage$4,76188%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,424 in reported general payments places this provider in the 85th percentile of 382 podiatrist providers in New Jersey.

See all podiatrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$300,574
Medicare patients
900
Services billed
4,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole26$26,604
Ketoconazole119$3,025
Ciclopirox108$2,877
Mupirocin125$959
Diclofenac Sodium23$648
Gabapentin36$429
Doxycycline Hyclate45$427
Terbinafine Hcl11$214
Allopurinol25$200
Ammonium Lactate22$184
CiclopiroxCiclopirox Olamine12$176
Cephalexin42$173
Triamcinolone Acetonide13$153
Methylprednisolone28$127
Naproxen21$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$31$26,60426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 382 podiatrist providers in New Jersey.

Other podiatrist in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →